Chong Kun Dang Pharmaceutical Corp.

KOSE:A185750 Stock Report

Market Cap: ₩1.2t

Chong Kun Dang Pharmaceutical Future Growth

Future criteria checks 0/6

Chong Kun Dang Pharmaceutical's earnings are forecast to decline at 16.7% per annum while its annual revenue is expected to grow at 3.3% per year. EPS is expected to decline by 18.3% per annum. Return on equity is forecast to be 11.6% in 3 years.

Key information

-16.7%

Earnings growth rate

-18.3%

EPS growth rate

Pharmaceuticals earnings growth31.7%
Revenue growth rate3.3%
Future return on equity11.6%
Analyst coverage

Good

Last updated28 Oct 2024

Recent future growth updates

Recent updates

Is Chong Kun Dang Pharmaceutical (KRX:185750) Using Too Much Debt?

Oct 24
Is Chong Kun Dang Pharmaceutical (KRX:185750) Using Too Much Debt?

Investors Aren't Buying Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Earnings

Sep 27
Investors Aren't Buying Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Earnings

Does Chong Kun Dang Pharmaceutical (KRX:185750) Deserve A Spot On Your Watchlist?

Sep 08
Does Chong Kun Dang Pharmaceutical (KRX:185750) Deserve A Spot On Your Watchlist?

Are Investors Undervaluing Chong Kun Dang Pharmaceutical Corp. (KRX:185750) By 41%?

Jul 30
Are Investors Undervaluing Chong Kun Dang Pharmaceutical Corp. (KRX:185750) By 41%?

Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel

Jun 12
Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel

Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly

May 27
Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly

A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)

Apr 09
A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)

Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?

Apr 19
Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?

Here's Why I Think Chong Kun Dang Pharmaceutical (KRX:185750) Is An Interesting Stock

Apr 05
Here's Why I Think Chong Kun Dang Pharmaceutical (KRX:185750) Is An Interesting Stock

Declining Stock and Solid Fundamentals: Is The Market Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750)?

Mar 09
Declining Stock and Solid Fundamentals: Is The Market Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750)?

Estimating The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)

Feb 24
Estimating The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)

The Chong Kun Dang Pharmaceutical (KRX:185750) Share Price Is Up 112% And Shareholders Are Boasting About It

Feb 11
The Chong Kun Dang Pharmaceutical (KRX:185750) Share Price Is Up 112% And Shareholders Are Boasting About It

Is Chong Kun Dang Pharmaceutical Corp. (KRX:185750) An Attractive Dividend Stock?

Jan 27
Is Chong Kun Dang Pharmaceutical Corp. (KRX:185750) An Attractive Dividend Stock?

Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?

Jan 12
Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?

With EPS Growth And More, Chong Kun Dang Pharmaceutical (KRX:185750) Is Interesting

Dec 28
With EPS Growth And More, Chong Kun Dang Pharmaceutical (KRX:185750) Is Interesting

What Kind Of Shareholders Hold The Majority In Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Shares?

Dec 09
What Kind Of Shareholders Hold The Majority In Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Shares?

Could The Market Be Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750) Given Its Attractive Financial Prospects?

Nov 24
Could The Market Be Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750) Given Its Attractive Financial Prospects?

Earnings and Revenue Growth Forecasts

KOSE:A185750 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,750,763122,929159,286180,8008
12/31/20251,667,488106,471141,286162,8638
12/31/20241,561,450119,780127,857153,7148
9/30/20241,675,678189,039119,750185,241N/A
6/30/20241,666,522212,788196,160257,825N/A
3/31/20241,665,726202,243249,344321,128N/A
12/31/20231,669,404212,521249,354318,160N/A
9/30/20231,561,851136,097134,793206,913N/A
6/30/20231,542,134119,04552,863125,597N/A
3/31/20231,512,15499,38151,004103,844N/A
12/31/20221,488,34580,95314,67067,734N/A
9/30/20221,453,15970,692-31,83512,119N/A
6/30/20221,411,50844,292-24,84419,113N/A
3/31/20221,373,01845,096-35,29513,964N/A
12/31/20211,343,55942,720-38,93012,904N/A
9/30/20211,318,91452,31915,26866,304N/A
6/30/20211,335,06685,11638,97887,610N/A
3/31/20211,321,55888,79249,40892,670N/A
12/31/20201,303,00691,63367,506104,324N/A
9/30/20201,263,96596,31661,95595,132N/A
6/30/20201,186,15675,88960,98992,526N/A
3/31/20201,138,68960,91648,31076,123N/A
12/31/20191,079,33853,88252,42977,291N/A
9/30/20191,046,38751,32766,18089,129N/A
6/30/20191,000,91050,37855,22275,429N/A
3/31/2019971,68850,42227,15850,953N/A
12/31/2018956,21942,39917,98842,628N/A
9/30/2018934,98243,6824,84733,677N/A
6/30/2018919,53446,688N/A48,954N/A
3/31/2018893,20445,204N/A65,370N/A
12/31/2017884,36353,807N/A81,673N/A
12/31/2016831,98640,946N/A57,786N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A185750's earnings are forecast to decline over the next 3 years (-16.7% per year).

Earnings vs Market: A185750's earnings are forecast to decline over the next 3 years (-16.7% per year).

High Growth Earnings: A185750's earnings are forecast to decline over the next 3 years.

Revenue vs Market: A185750's revenue (3.3% per year) is forecast to grow slower than the KR market (9.3% per year).

High Growth Revenue: A185750's revenue (3.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A185750's Return on Equity is forecast to be low in 3 years time (11.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y